OBJECTIVE: "…to investigate asenapine in preventing the recurrence of any mood episode in subjects with bipolar I disorder…"
METHODS

STUDY DESIGN
• 
OUTCOMES
• Primary efficacy outcome was time to recurrence of any mood event during double-blind treatment o Recurrence-requirement or initiation of non-study medication to treat manic, depressive, or mixed symptoms, need for psychiatric hospitalization, study discontinuation because of mood event, or a total YMRS or MADRS score > 16 • Secondary outcomes of interest were rate of recurrence for manic, mixed, and depressive mood episodes and time to discontinuation for any reason
STATISTICS
• Kaplan-Meier used to estimate time to first recurrence of any, manic, mixed, and depressive episodes • Difference in survival curves evaluated using two-sided log rank test • Cox proportional hazard models used to estimate hazard ratios
RESULTS
• 171 (67.9%) completed double-blind treatment (highest in asenapine group) 
